High-dose fulvestrant filed for Japanese approval for breast cancer
06 January 2010
Ian Haydock
Please Login to read the full article.
06 January 2010
Ian Haydock
ian.haydock@informa.com
AstraZeneca has made a submission in Japan for the approval of fulvestrant, for the treatment of postmenopausal women with advanced or recurrent breast cancer.
The oestrogen receptor modulator was approved as Faslodex in the US in 2002 and in the EU in 2004, as a second-line therapy for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Telaprevir and fingolimod approved in Japan as ministry confirms recommendations
- AZ weathers another storm as NICE prepares final blow for Faslodex
- Year end submissions for Novartis' Afinitor in breast cancer after trial stopped early
- NICE: AstraZeneca's Faslodex in breast cancer not 'a good use of resources'
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
